Skip to main content
Premium Trial:

Request an Annual Quote

Revenues Down, Losses Up for Sequenom in Q1

NEW YORK, April 29 (GenomeWeb News) - Sequenom today reported dwindling revenues and increased losses for the first quarter.

 

Revenues totaled $5.1 million, down from $7.4 million during the same quarter last year. "We see the number of new account opportunities for high-throughput genotyping reaching saturation," said CFO Steve Zaniboni in a statement.

 

Sequenom's R&D expenses increased slightly, to $6 million, from $5.9 million during the year-ago quarter.

 

The company recorded a net loss of $9.9 million, or $.25 per share, up from $8.5 million, or $.22 per share, during the first quarter of 2003.

 

As of March 31, San Diego-based Sequenom had $59.5 million in cash, cash equivalents, short-term investments and restricted cash.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.